A synthetic antibody treatment developed by Regeneron reduced the risk of contracting a symptomatic form of Covid-19 by 80%, up to eight months after receiving the injection, the American biotechnology firm announced on Monday.
These results “are particularly important for those who do not respond to vaccines against Covid-19, including immunocompromised people,” said Myron Cohen, a scientist at the University of North Carolina, in charge of conducting the trials funded by the American state.
No one who received treatment was hospitalized
The study was carried out with more than 1,600 people. Half of them received the treatment (an injection), the other a placebo. During a follow-up period of two to eight months, seven cases of Covid were identified in the group who received the treatment compared to 38 in those who received the placebo, a reduction of more than 80%.
But above all, no one who had received the treatment was hospitalized, compared to six in the placebo group.
Trump, the best known beneficiary
This treatment, of which one of its most famous beneficiaries is probably former President Donald Trump, has emergency authorization in the United States for people at risk.
“A single dose of REGEN-COV provides long-term protection against Covid-19, including at times of very high exposure, in one’s home, and longer term during wider continuous exposure,” said George. Yancopoulos Chief Scientific Officer at Regeneron.
